PATIENTS RECEIVING HEMODIALYSIS DO NOT LOSE SARS-COV-2 ANTIBODIES MORE RAPIDLY THAN NON-RENAL CONTROLS: A PROSPECTIVE COHORT STUDY

Simple item page
dc.contributor.authorParshina, Ekaterina
dc.contributor.authorZulkarnaev, Alexey
dc.contributor.authorTolkach, Alexey
dc.contributor.authorIvanov, Andrey
dc.contributor.authorKislyy, Pavel
dc.contributor.authorGaipov, Abduzhappar
dc.date.accessioned2023-03-28T06:06:54Z
dc.date.available2023-03-28T06:06:54Z
dc.date.issued2022
dc.description.abstractBackground Patients with end-stage kidney disease receiving maintenance hemodialysis (HD) are at increased risk for mortality after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared with the general population. However, it is currently unknown whether the long-term SARS-CoV-2 humoral and cellular immune responses in patients receiving HD are comparable to individuals with normal kidney function. Method The prospective cohort study included 24 patients treated with maintenance HD and 27 non-renal controls with confirmed history of coronavirus disease (COVID-19). In all participants the levels of specific IgG were quantified at three timepoints: 10, 18, and 26 weeks from disease onset. In a subgroup of patients, specific T-cell responses were evaluated. Results The seropositivity rate declined in controls over time and was 85% and 70.4% at weeks 18 and 26, respectively. All HD patients remained seropositive over the study period. Seropositivity rate at week 26 was greater among patients receiving HD: RR = 1.4 [95%CI: 1.17–1.94] (reciprocal of RR = 0.7 [95% CI: 0.52–0.86]), p = 0.0064. In both groups, IgG levels decreased from week 10 to week 26, but antibodies vanished more rapidly in controls than in HD group (ANOVA p = 0.0012). The magnitude of T-cell response was significantly lower in controls than in HD patients at weeks 10 (p = 0.019) and 26 (p = 0.0098) after COVID-19 diagnosis, but not at week 18. Conclusion Compared with non-renal adults, patients receiving HD maintain significant long-term humoral and cellular immune responses following natural COVID-19.en_US
dc.identifier.citationParshina, E., Zulkarnaev, A., Tolkach, A., Ivanov, A. V., Kislyy, P., & Gaipov, A. (2022). Patients receiving hemodialysis do not lose SARS-CoV-2 antibodies more rapidly than non-renal controls: a prospective cohort study. Renal Failure, 44(1), 391–397. https://doi.org/10.1080/0886022x.2022.2042310en_US
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/6984
dc.language.isoenen_US
dc.publisherRenal Failureen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectType of access: Open Accessen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjecthemodialysisen_US
dc.subjectantibodyen_US
dc.subjectcellular immunityen_US
dc.titlePATIENTS RECEIVING HEMODIALYSIS DO NOT LOSE SARS-COV-2 ANTIBODIES MORE RAPIDLY THAN NON-RENAL CONTROLS: A PROSPECTIVE COHORT STUDYen_US
dc.typeArticleen_US
workflow.import.sourcescience

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Patients receiving hemodialysis do not lose SARS CoV 2 antibodies more rapidly than non renal controls a prospective cohort study.pdf
Size:
1.88 MB
Format:
Adobe Portable Document Format
Description:
article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6.28 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Articles